MEGF6

Across TCGA pan-cancer cohorts, MEGF6 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MEGF6 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MEGF6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEGF6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LIHC, READ, and PRAD are the cancer types where MEGF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.178	0.620	.005	9	view →
READ	OS	Median	All	0.191	0.676	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.268	0.711	.008	4	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →
HNSC	DFS	Median	III,IV	0.857	0.293	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MEGF6–LIHC (OS)

Open the LIHC breakdown →